INDIVIDUAL ARTICLE: NECOM 3: A Practical Algorithm for the Management of Radiation Therapy-Related Acute Radiation Dermatitis

November 2023 | Volume 22 | Issue 11 | SF400354s3 | Copyright © November 2023


Published online October 11, 2023

Ada Girnita MD PhDa, Peter Bjerring MD PhD FEADVb, Sampsa Kauppi MDc, Charles W. Lynde MD FRCPCd, Maxwell B. Sauder MD FRCPC DABDe, Anneke Andriessen PhDf

aSkin Cancer Center Karolinska University Hospital, Stockholm, Sweden  
bDepartment of Dermatology, Aalborg University Hospital, Aalborg, Denmark  
cPrivate practice, Terveystalo and Epilaser Oy, Finland  
dDepartment of Medicine University of Toronto, Toronto, ON, Canada; Lynderm Research, Markham, ON, Canada  
ePrincess Margaret Cancer Centre, Toronto, ON, Canada; Department of Medicine University of Toronto, Toronto, ON, Canada
fRadboud UMC, Nijmegen and Andriessen Consultants, Malden, The Netherlands 



Limitations
Prospective clinical trials that evaluate the efficacy of a practical algorithm for ARD are currently unavailable. Furthermore, the evidence base lacks supporting recommendations for preventing and treating ARD. 

CONCLUSION

Frequently, cancer patients receiving RT suffer from ARD leading to pruritus and pain, decreased QoL and morbidity, and treatment interruptions. Patient education on the prevention of ARD and treatment recommendations given in the NECOM 3 algorithm may help prevent and manage ARD and improve the overall care of cancer patients receiving RT.

DISCLOSURES

An unrestricted educational grant from La Roche-Posay Nordic European Countries supported this work. All authors contributed, reviewed the manuscript, and agreed with its content and publication.

REFERENCES

  1. Dyba T, Randi G, Bray F, et al. The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer. 2021;157:308-347. 
  2. Hemminki J, Försti A, Hemminki A, et al. Survival trends in solid cancers in the Nordic countries through 50 years. Eur J Cancer. 2022;175:77-85.
  3. World Health Organization. Cancer Today. https://gco.iarc.fr/today/home. Accessed 7 July 2022.
  4. Int Agency Research Cancer, WHO, NORDCAN 2022. Version: 9.2-23.06.2022. nordcan.iarc.fr/en/database. Accessed 7 July 2022.
  5. Siegel RL, Miller KD, Ahmedin J. Cancer statistics 2022. CA Cancer J Clin. 2022;72:7-33.
  6. Girnita A, Lorentzen H, Kauppi S, et al. Skincare for cancer patients in Scandinavia. J Drugs Dermatol. 2021;20(12):s4-s14. doi: 10.36849/jdd.m1221 
  7. Girnita A, Lorentzen H, Kauppi S, et al. Nordic European Cutaneous Oncodermatology Management (NECOM) 2: skincare algorithm for cancer patients and survivors. J Drugs Dermatol. 2023;22(1):3595573-359557310. PIMD: 36607766 
  8. Brouwers M, Kho ME, Browman GP, et al. AGREE Next Steps Consortium. AGREE II: advancing guideline development, reporting and evaluation in healthcare. Can Med Assoc J. 2010;182:E839-842. 
  9. Trevelyan EG, Robinson N. Delphi methodology in health research: how to do it? Eur J Integ Med. 2015;7(4):423-428.
  10. Begolka WS, Elston DM, Beutner KR. American Academy of Dermatology evidence-based guideline development process: responding to new challenges and establishing transparency. J Am Acad Dermatol. 2011;64(6):e105-112.
  11. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2017, National Cancer Institute. Published April 2020. https://seer.cancer.gov/csr/1975_2017/ 
  12. Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707-1716. doi: 10.1016/s0140-6736(11)61629-24. 
  13. Rzepecki A, Birnbaum M, Ohri N, et al. Characterizing the effects of radiation dermatitis on quality of life: a prospective survey-based study. J Am Acad Dermatol. 2019:S0190-9622(19)30425-6.
  14. Ambrosini V, Kunikowska J, Baudin E, et al. Consensus on molecular imaging and theranostics in neuroendocrine neo-plasms. Eur J Cancer. 2021;146:56-73.
  15. Jahn U, Ilan E, Sandstrom M, et al. Peptide receptor radionuclide therapy (PRRT) with (177) Lu-Dotatate; differences in tumor dosimetry, vascularity, and lesion metrics in pancreatic and small intestinal neuroendocrine neoplasms. Cancers (Basel). 2021;13:962.
  16. Citrin DE. Recent developments in radiotherapy. N Engl J Med. 2017;377(11):1065–1075.
  17. Royce TJ, Qureshi MM, Truong MT. Radiotherapy utilization and fractionation patterns during the first course of cancer treatment in the United States from 2004 to 2014. J Am Coll Radiol. 2018;15:1558-1564.
  18. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660 2. 
  19. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33. doi: 10.3322/caac.21654 
  20. Holli K, Hietanen P, Saaristo R, et al. Radiotherapy after segmental resection of breast cancer with favorable prognostic features: 12-year follow-up results of a randomized trial. J Clin Oncol. 2009;27(6):927-932. 
  21. Leventhal J, Young MR. Radiation dermatitis: recognition, prevention, and management. Oncol (Williston Park). 2017;31(12):885-887.
  22. Ramseier JY, Ferreira MN, Leventhal JS. Dermatologic toxicities associated with radiation therapy in women with breast cancer. Int J Women's Dermatol. 2020;6(5):349-356. doi: 10.1016/j. ijwd.2020.07.015 
  23. trials. Clin Breast Cancer. 2018;18(5):e825-840. doi: 10.1016/j. clbc. 2018.06.015 
  24. Pasquier D, Bataille B, Le Tinier F, et al. Correlation between toxicity and dosimetric parameters for adjuvant intensity modulated radiation therapy of breast cancer: a prospective study. Sci Rep. 2021;11(1):3626. doi: 10.1038/s41598-021-83159-3 
  25. Hennequin C, Barillot I, Azria D, et al. Radiotherapy of breast cancer. Cancer Radiother. 2016;20:139-146. 
  26. Shaitelman SF, Schlembach PJ, ArzuI et al. Acute and short-term toxic effects of conventionally fractionated vs. hypofractionated whole-breast radiation: a randomized clinical trial. JAMA Oncol. 2015;1:931-941. 
  27. Haruna F, Lipsett A, Marignol L. Topical management of acute radiation dermatitis in breast cancer patients: a systematic review and meta-analysis. Anticancer Res. 2017;37:5343-5353.
  28. Chan RJ, Larsen E, Chan P. Re-examining the evidence in radiation dermatitis management literature: an overview and a critical appraisal of systematic reviews. Int J Radiat Oncol Biol Phys. 2012;84:357-362. 
  29. Schmeel LC, Koch D, Schmeel FC, et al. Acute radiation-induced skin toxicity in hypofractionated vs. conventional whole-breast irradiation: an objective, randomized multicenter assessment using spectrophotometry. Radiother Oncol. 2020;146:172-179.
  30. Finkelstein S, Kanee L, Behroozian T, et al. Comparison of clinical practice guidelines on radiation dermatitis: a narrative review. Support Care Cancer. 2022;30:4663-4674.
  31. Fuzissaki MA, Paiva CE, Oliveira MA, et al. The impact of radiodermatitis on breast cancer patients' quality of life during radiotherapy: a prospective cohort study. J Pain Symptom Manag. 2019; 58(1):92-99.e1. doi: 10.1016/j.jpainsymman.2019.03.017 
  32. United States Department of Health and Human Services, National Institutes of Health, National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Bethesda, MD: nci; 2010. Version 5. Available at: evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed 7 July 2022.
  33. Wei J, Meng L, Jiang X, et al. Radiation-induced skin reactions: mechanism and treatment. Cancer Manag Res. 2019;11:167-177.
  34. National Cancer Institute (NIH). Publication No.17-7157. Radiation Therapy and You: Support for People with Cancer. 2016(10):1-56. Available at: https://www.cancer.gov/publications/patient-education/radiation-therapy-and-you. Accessed 7 July 2022.
  35. Rosenthal A, Irailevich R, Mov R. Management of acute radiation dermatitis: a review of the literature and proposal for treatment algorithm. J Am Acad Dermatol. 2019;81(8):558-567.
  36. Ferreira EB, Vasques CI, Gadia R, et al. Topical interventions to prevent acute radiation dermatitis in head and neck cancer patients: a systematic review. Support Care Cancer. 2017;25:1001-1011.
  37. Berger A, Regueiro C, Hijal T, et al. Interest of supportive and barrier-protective skin care products in the daily prevention and treatment of cutaneous toxicity during radiotherapy for breast cancer. Breast Ca: Basic Clin Research. 2018;12:1-7. doi.org/10.1177/1178223417752772
  38. Farrugia CE, Burke ES, Haley ME, et al. The use of aloe vera in cancer radiation: an updated comprehensive review. Comp Ther Clin Pract. 2019;35:126-130.
  39. Cosentino D, Piro F. Hyaluronic acid for treatment of the radiation therapy side effects: a systematic review. Eur Rev Med Pharmacol Sci. 2018;22(21):7562-7572.
  40. Presta G, Puliatti A, Bonetti L, et al. Effectiveness of hyaluronic acid gel (Jalosome soothing gel) for the treatment of radiodermatitis in a patient receiving head and neck radiotherapy associated with cetuximab: a case report and review. Int Wound J. 2019;16(6):1433-1439.
  41. Russi EG, Moretto F, Rampino M, et al. Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: literature review and consensus. Crit Rev Oncol Hematol. 2015;96(1):167-182.
  42. McQuestion M. Evidence-based skin care management in radiation therapy: clinical update. Semin Oncol Nurs. 2011;27:e1-e17.
  43. Schnur JB, Love B, Scheckner BL, et al. A systematic review of patient-rated measures of radiodermatitis in breast cancer radiotherapy. Am J Clin Oncol. 2011;34(5):529-536. 
  44. Hegedus F, Mathew LM, Schwartz RA. Radiation dermatitis: an overview. Int J Dermatol. 2017;9:909-914.
  45. Salzmann M, Marmé F, Hassel JC. Prophylaxis and management of skin toxicities. Breast Care. 2019;14:72-77. doi.org/10.1159/000497232 
  46. Hindley A, Zain Z, Wood L, et al. Mometasone furoate cream reduces acute radiation dermatitis in patients receiving breast radiation therapy: results of a randomized trial. Int J Radiat Oncol Biol Phys. 2014;90:748-755. doi: 10.1016/j.ijrobp.2014.06.033
  47. Ho AY, Olm-Shipman M, Zhang Z, et al. A randomized trial of mometasone furoate 0.1% to reduce high-grade acute radiation dermatitis in breast cancer patients receiving postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2018;101(2):325-333 
  48. Zenda S, Yamaguchi T, Yokota T, et al. Topical steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy: the study protocol of J-SUPPORT 1602 (TOPICS study), a randomized double-blinded phase 3 trial. Bio Med Central Cancer. 2018;18(1):873.
  49. Miller RC, Schwartz DJ, Sloan JA, et al. Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4. Int J Radiat Oncol Biol Phys. 2011;79:1460-1466. doi: 10.1016/j.ijrobp.2010.01.031
  50. Ulff E, Maroti M, Serup J, et al. A potent steroid cream is superior to emollients in reducing acute radiation dermatitis in breast cancer patients treated with adjuvant radiotherapy. A randomised study of betamethasone versus 2 moisturizing creams. Radiother Oncol. 2013;108:287-292. doi: 10.1016/j.radonc.2013.05.033
  51. Neben-Wittich MA, Atherton PJ, Schwartz DJ, et al. Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4). Int J Radiat Oncol Biol Phys. 2011;81:397-402.
  52. Liao Y, Feng G, Dai T, et al. Randomized, self-controlled, prospective assessment of the efficacy of mometasone furoate local application in reducing acute radiation dermatitis in patients with head and neck squamous cell carcinomas. Medicine (Baltimore). 2019;98(52):e18230. doi: 10.1097/MD.0000000000018230. 
  53. Ghasemi A, Ghashghai Z, Akbari J, et al. Topical atorvastatin 1% for prevention of skin toxicity in patients receiving radiation therapy for breast cancer: a randomized, double-blind, placebo-controlled trial. Eur J Clin Pharmacol. 2018;6:1-8.
  54. Baumann BC, Verginadis II, Zeng C, et al. Assessing the validity of clinician advice that patients avoid the use of topical agents before daily radiotherapy treatments. JAMA Oncol. 2018;4(12):1742-1748. doi: 10.1001/jamaoncol.2018.4292.
  55. Iacovelli NA, Galaverni M, Cavallo A, et al. Prevention and treatment of radiation-induced acute dermatitis in head and neck cancer patients: a systematic review. Future Oncol. 2018;14(3):291-305. doi.org/10.2217/fon-2017-0359
  56. Ferreira EB, Ciol MA, Vasques CI, et al. Gel of chamomile vs. urea cream to prevent acute radiation dermatitis in patients with head and neck cancer: a randomized controlled trial. J Adv Nurs. 2016;72(8):1926-1934.
  57. Schneider F, Danski MT, Vayego SA. Usage of Calendula officinalis in the prevention and treatment of radiodermatitis: a randomized double-blind controlled clinical trial. Rev Esc Enferm USP. 2015;49(2):221-228.
  58. Kang HC, Ahn SD, Choi DH, et al. The safety and efficacy of EGF-based cream for the prevention of radiotherapy-induced skin injury: results from a multicenter observational study. Rad Oncol J. 2014;32(3):156. 
  59. Abbas H, Bensadoun RJ. Trolamine emulsion for the prevention of radiation dermatitis in patients with squamous cell carcinoma of the head and neck. Support Care Cancer. 2012;20(1):185-190.
  60. Sharp L, Finnilä K, Johansson H, et al. No differences between Calendula cream and aqueous cream in the prevention of acute radiation skin reactions-results from a randomised blinded trial. Eur J Oncol Nurs. 2013;17:429-435.
  61. Kong M, Hong SE. Topical use of recombinant human epidermal growth factor (EGF)-based cream to prevent radiation dermatitis in breast cancer patients: a single-blind randomized preliminary study. Asian Pac J Cancer Prev. 2013;14(8):4859-4864.
  62. Graham PH, Plant N, Graham JL, et al. A paired, double-blind, randomized comparison of a moisturizing durable barrier cream to 10% glycerine cream in the prophylactic management of postmastectomy irradiation skin care: Trans-Tasman Radiation Oncology Group (TROG) 04.01. Int J Radiat Oncol Biol Phys. 2013;86:45-50. doi: 10.1016/j.ijrobp.2012.12.009
  63. Pinnix C. Perkins G.H.Strom E.A. et al. Topical hyaluronic acid vs. standard of care for the prevention of radiation dermatitis after adjuvant radiotherapy for breast cancer: single-blind randomized phase III clinical trial. Int J Radiat Oncol Biol Phys. 2012;83:1089-1094.
  64. Chan RJ, Blades R, Jones L, et al. A single-blind, randomised controlled trial of StrataXRT® -- a silicone-based film-forming gel dressing for prophylaxis and management of radiation dermatitis in head and neck cancer patients. Radiother Oncol. 2019;139:72-78.
  65. Wooding H, Yan J, Yuan L, et al. The effect of Mepitel Film on acute radiation-induced skin reactions in head and neck cancer patients: a feasibility study. Br J Radiol. 2018;91:20170298.
  66. Herst PM, Bennett NC, Sutherland AE, et al. Prophylactic use of Mepitel Film prevents radiation-induced moist desquamation in an intra-patient randomised controlled clinical trial of 78 breast cancer patients. Radiother Oncol. 2014;110:137-143.
  67. Zhong WH, Tang QF, Hu LY, et al. Mepilex Lite dressings for managing acute radiation dermatitis in nasopharyngeal carcinoma patients: a systematic controlled clinical trial. Med Oncol. 2013;30(4):761. 
  68. Diggelmann KV, Zytkovicz AE, Tuaine JM, et al. Mepilex Lite dressings for the management of radiation-induced erythema: a systematic inpatient controlled clinical trial. Br J Radiol. 2010;83:971-978.
  69. Aquino-Parsons C, Lomas S, Smith K, et al. Phase III study of silver leaf nylon dressing vs standard care for reduction of inframammary moist desquamation in patients undergoing adjuvant whole breast radiation therapy. J Med Imag Rad Sci. 2010;41(4):215-221.
  70. Gold MH, Andriessen A, Bhatia AC, et al. Topical stabilized acid: The future gold standard for wound care and scar management in dermatologic and plastic surgery procedures. J Cosmet Dermatol. 2020;19(2):270-277. doi: 10.1111/jocd.13280
  71. Hemati S, Asnaashari O, Sarvizadeh M, et al. Topical silver sulfadiazine for the prevention of acute dermatitis during irradiation for breast cancer. Support Care Cancer. 2012;20:1613-1618. doi: 10.1007/s00520-011-1250-5
  72. Aziz Z, Abu SF, Chong NJ. A systematic review of silver-containing dressings and topical silver agents (used with dressings) for burn wounds. Burns. 2012;38(3):307-318.
  73. Sheckter CC, Van Vliet MM, Krishnan NM, Garner WL. Cost-effectiveness comparison between topical silver sulfadiazine and enclosed silver dressing for partial-thickness burn treatment. J Burn Care Res. 2014;35(4):284-290.
  74. Vloemans AFPM, Soesman AM, Kreis RW, et al. A newly developed hydrofiber dressing in the treatment of partial thickness burns. Burns. 2001;27(2):167-173.
  75. Rashaan ZM, Krijnen P, Klamer RR, et al. Nonsilver treatment vs. silver sulfadiazine in treatment of partial-thickness burn wounds in children: a systematic review and meta-analysis. Wound Repair Regen. 2014; 22:473.
  76. Chen ST, Molina GE, Lo JA, et al. Dermatology consultation reduces interruption of oncologic management among hospitalized patients with irAEs. J Am Acad Dermatol. 2020;82(4):994-996.  
  77. Barrios DM, Phillips GS, Feites-Martinez A, et al. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. J Eur Acad Dermatol Venereol. 2020;34(6):1340-1347. doi: 10.1111/jdv.16159
  78. Barrios DCK, Phillips G, Lucas AS, et al. Anticancer therapy interruption and diagnostic concordance between referring clinicians and dermatologists at MSKCC. J Am Med Assn Dermatol. 2017;76(6):AB45.

AUTHOR CORRESPONDENCE

Anneke E. Andriessen PhD anneke.a@tiscali.nl
Close Menu